





Safe Administration of Amphotericin B deoxycholate

Treating Cryptococcal Meningitis













Workshop Learning Objectives

- To demonstrate the safe administration of amphotericin B deoxycholate (AmB).
- To describe the management of meningo-encephalitis treatment toxicity.
- For more information see online Cryptococcal Meningitis module sections : *Treating HIV-associated Cryptococcal Meningitis*

Recommended CCM induction regimens for LMICs as a result of ACTA – WHO Guidance 2018

- In order of recommendation (depending on possibility of safe AmB administration and availability of 5-FC):
- 1 week AmB (1mg/kg/day) + 5-FC (100mg/kg/day)
 -gold standard for LMICs
- 2 weeks Fluconazole (1200mg daily) + 5-FC (100mg/kg/day) -alternative
- 3rd line = 2 weeks AmB 1mg/kg/day + Fluconazole 1200mg daily

LMIC: Low- and middle-income countries, AmB: Amphotericin B deoxycholate, 5-FC: Flucytosine

Safe Administration of Amphotericin B deoxycholate



- Used for treating patients with confirmed cryptococcal meningoencephalitis.
- Given as part of induction phase of therapy in conjunction with Flucytosine (5-FC), and where 5-FC unavailable fluconazole.

Please refer to the CCM poster, safe 5-FC administration poster and safe 5-FC administration workshop



How to Administer AmB?

- The dose of AmB to be administered daily is 1mg/kg/day
- Doses usually range between 25mg and 80mg based on patient weight.
- A single infusion is given once daily over 4 hours.
- AmB comes in 50mg vials of yellow powder which must be reconstituted with 10ml of water for injection.



Pre-hydration before Administration

• AmB can cause LOW POTASSIUM – this can be FATAL.



- Administer 1L Normal Saline with Potassium chloride KCl (20mmol) over a minimum 2 hour period prior to AmB infusion. Ideally, pre-hydration should be given first thing in the morning.
- Do not supplement with potassium if the patient has pre-existing renal impairment or hyperkalaemia.
- If significant hypokalaemia (K <3.3mmol/L), increase potassium supplementation to one or two 8mEq KCL tablets three times daily. Monitor potassium minimum twice weekly.



Administration – Step 1

- AmB comes in 50mg vials of yellow powder which must be reconstituted with 10ml of water for injection.
- The dose is then drawn up according to the following table:

(Aseptic technique should be observed during this process)

AmB: Amphotericin B deoxycholate

AmBd dose	Amount drawn up from vial(s)	Number of vials	
25mg	5ml	1	
30mg	6ml	1	
35mg	7ml	1	
40mg	8ml	1	
45mg	9ml	1	
50mg	10ml	1	
55mg	11ml	2	
60mg	12ml	2	
65mg	13ml	2	
70mg	14ml	2	
75mg	15ml	2	
80mg	16ml	2	



Administration - Step 2

- Inject the AmB dose into a 1000ml bag of 5% Dextrose or 10% Dextrose. Shake to mix.
- *NEVER* mix AmB with Normal Saline as the drug will precipitate.
- Administer AmB over 4 hours (no faster) to avoid arrhythmias, ideally in the morning.
- Once mixed, the bag must be administered within 24 hours or else discarded.
- The line used for AmB should not be used for administering any other drugs. AmB: Amphotericin B deoxycholate



Potassium (K) replacement

Please refer to the CCM poster on safe AmB administration

- ALL patients on AmB should receive oral potassium supplementation (except if contraindicated – hyperkalaemia or pre-existing renal impairment).
- IV 20 mmol KCl mixed in 1litre Normal saline infused over minimum 2 hours before AmB administration, ideally first thing in the morning.
- If significant hypokalaemia (K <3.3mmol/l), increase potassium supplementation to one or two 8mEq KCL tablets three times daily. Monitor potassium minimum twice weekly.
- Max infusion rate 10mmol /hr by peripheral IV (or 20mmol per hour by central IV). Ampoule should be diluted in at least 100mL of Normal Saline or 5% Dextrose
- See WHO 2018 guidelines for more details.

Hr: hour IV: Intravenous Max: Maximal AmB: Amphotericin B deoxycholate

Potassium (K) replacement

- Remember Maximal infusion rate KCl 10mmol /hr by peripheral IV.
- Routine prehydration with IV KCl 20mmol must be given over a minimum period of 2 hours.
- 1 KCl ampoule should be diluted in at least 100mL of Normal Saline.
- CAUTION-HCW training on safe KCl administration and adequate monitoring needs to be in place.
- Patients with hypokalaemia despite maximal oral K replacement may require additional IV KCl replacement if sufficient monitoring possible and training in place.

Hr: hour IV: Intravenous K: Potassium KCL: Potassium Chloride HCW: healthcare worker



Magnesium (Mg) replacement

- ALL patients (unless contraindicated) should be routinely given oral magnesium supplementation
- 3 tablets daily (12mmols/day Mg glycerophosphate or chloride) to prevent hypomagnesaemia.
- If persistently low serum potassium for >2 days (serum K+ levels <3.0 mmol/L) request Mg measurement (if available).
- Hypokalaemia despite adequate replacement ASSUME HYPOMAGNESEMIA.
- Patients receive 5g Magnesium sulfate IV daily until serum K+ levels normalize.
- If new seizure develops in setting of hypokalaemia, consider giving Mg Sulfate IV.

Monitoring patients on AmB - Thrombophlebitis



- Common side effect of AmB. Lines must be checked for symptoms and signs of thrombophlebitis on a DAILY basis.
- Monitor the patient daily for symptoms & signs of thrombophlebitis – pain or tenderness.
- The peripheral line MUST be flushed with 5% dextrose for injection before and after administration of AmB.




Thrombophlebitis of right arm secondary to administration of Amphotericin B deoxycholate

AmB: Amphotericin B deoxycholate

Monitoring patients on AmB - Thrombophlebitis

- Re-site line at first report of pain or tenderness.
- Swab site of thrombophlebitis.
- Send blood cultures.
- If severe thrombophlebitis give antibiotics Flucoxacillin first line but check local antibiotic sensitivities.
- Flucolaxacillin covers Methicillin Sensitive Staphylococcus Aureus (MSSA) + Methicillin Sensitive Coagulase Negative Staphylococcus (MS CNS).

AmB: Amphotericin B deoxycholate










Monitoring patients on AmB - Rigors

- Monitor full blood count (minimum baseline & weekly) & renal function (minimum baseline & twice weekly).
- If AmB-induced rigors occur, the infusion length can be increased and/or acetaminophen/paracetamol (650-1000mg) PO/PR administered 30 minutes prior to AmB administration.



Renal toxicity Amphotericin B

• If creatinine rises up to 2.5 mg/dl (220 μmol/l):



If stable or improving, but still above 220 µmol/l: institute alternate day dosing (1 mg/kg q 4 hours)

- If creatinine is increasing do not give amphotericin B and check again after 24 hours:
- If stable or improving institute daily or alternate day dosing as above
- If creatinine still increasing: stop amphotericin B and switch to fluconazole (1200 mg +5-FC for first 2 weeks of antifungal therapy) adjusting its dose for renal impairment.
- AVOID other nephrotoxic agents such as aminoglycosides and NSAIDs if possible.

AmB: Amphotericin B deoxycholate NSAIDS: Non-steroidal anti-inflammatory drugs



Amphotericin B renal impairment

- Ensure adequate hydration.
- If creatinine remains high or climbs despite increased hydration then switch to second line induction regimen – 2 weeks fluconazole + 5-FC.
- Avoid nephrotoxic drugs such as NSAIDs including ibuprofen and aminoglycosides.
- Monitor electrolytes closely acute renal failure can lead to life threatening hyperkalaemia.

AmB: Amphotericin B deoxycholate 5-FC: Flucytosine NSAIDS: Non-steroidal anti-inflammatory drugs



AmB Treatment Monitoring

Schedule for minimum laboratory monitoring required for 1 week AmB + 5FC gold standard regimen for CCM

		Wee	ek 1 AmB	administ				
	Day of Treatment	1	3	4	5	7		
	Minimum Laboratory	Potassium (K) Creatinine (Creat)		K Creat		K Creat		
	Monitoring	Haemoglobin (HB)		НВ		НВ		
WHO guidance on safe AmB administration (1-2 weeks duration)-WHO guidelines								
	Monitoring (adults, adolescents and children)							
		Serum potassiu	Serum potassium			Baseline and 2–3 times weekly (especially in the second week of amphotericin B administration)		
		Serum creatinin	Serum creatinine			Baseline and 2–3 times weekly (especially in the second week of amphotericin B administration)		
AmB: Amp	bhotericin B deoxych	olate Haemoglobin	Haemoglobin			Baseline and	Baseline and weekly	



Authors and affiliations

• St George's University of London

Mr Muirgen Stack – Education lead

Dr Angela Loyse – Academic lead

Prof Tom Harrison

Prof Anne-Marie Reid (previous Dean of Education)

Ms Sarah Burton

Dr Tihana Bicanic

Dr Sile Molloy

Ms Ida Kolte

Institut Pasteur, France
 Ms Aude Sturny-Leclère - Laboratory lead
 Dr Timothée Boyer-Chammard – Clinical lead
 Prof Olivier Lortholary

• National Institute Communicable Diseases, South Africa

Dr Nelesh Govender

- UNC Project Lilongwe, Malawi
 Dr Cecilia Kanyama
- National Institute for Medical Research, Tanzania


Dr Sayoki Mfinanga

Hôpital Central Yaoundé, Cameroon/ANRS Dr Charles Kouanfack



Copyright, disclaimer and citation

- This work is licensed under the Creative Commons Attribution 4.0 International License (CC BY-NC 4.0).
- All figures are reproduced with permission where possible.
- The information within this workshop is for guidance only and does not replace local and international guidelines.



Suggested Citation:

DREAMM Clinical Training: HIV–associated Cryptococcal Meningitis. DREAMM Project 2018, St George's University of London, UK. figshare. Available at DOI: 10.24376/rd.sgul.7398596